These findings helped to explain why a subset of colorectal cancer patients did not respond to immunotherapy targeting PD1/PD-L1 or CTLA4 (61, 62), and offered evidence for the use of anti-LAG3 immunotherapy for colorectal cancers (63, 64). Here, LAG3 is linked to colorectal cancer.